BioSpace News Archive

Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it will participate in The Benchmark Company Healthcare House Call Virtual Video 1x1 Investor Conference on Wednesday, May 26, 2021 .

– Opinion based on the EMA’s Committee for Human Medicinal Products (CHMP) review of available data on sotrovimab (previously VIR-7831) for the early treatment of COVID-19 – – EU member states can use the CHMP positive scientific opinion when making national decisions about the early use of sotrovimab prior to EMA marketing authorization – –

The University of Pittsburgh’s Rehab Neural Engineering Labs demonstrate improved and faster grasping ability with artificial tactile feedback using Blackrock Neurotech’s NeuroPort System to restore function: Move Again and Feel Again.

SKYSONA is the first and only gene therapy recommended for approval for patients with CALD, a progressive, neurodegenerative disease As of the data cutoff date, 90% of patients (27/30) treated with SKYSONA in the pivotal ALD-102 clinical study met the primary endpoint of major functional disability (MFD)-free survival at two years of follow-up

Horizon Therapeutics plc Highlights Expanding R&D Efforts with Data Presentations at the EULAR European Congress of Rheumatology -- Key presentations feature investigational programs in rheumatoid arthritis and data evaluating KRYSTEXXA ® (pegloticase injection) for people with uncontrolled gout who received a kidney transplant --

Regulus Therapeutics Inc. today announced an incremental update from the first cohort of patients with ADPKD in its ongoing Phase 1b clinical trial of RGLS4326.

Perrigo Company plc (NYSE; TASE: PRGO), today announced that that President and CEO, Murray S. Kessler and CFO, Ray Silcock are scheduled to participate in investor meetings at the Barclays Consumer Spring Symposium on Tuesday, May 25.

Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that members of its executive leadership team will virtually present at the UBS Global Healthcare Virtual Conference at 11:00 a.m. ET on May 26, 2021.

SANUWAVE Health, Inc., a leading provider of next-generation wound care products and its JV partner Diversa S.A. have announced a new distribution agreement with Grupo Suprimed to market and sell the dermaPACE® System in the private healthcare market in Brazil.

Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the care of people living with rare genetic diseases of obesity, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending marketing authorization for setmelanotide for the treatment of obesity and the control of hunger